Abstract

Recently various strategies have been developed to exploit in a clinical setting the well established finding that T cells can specifically recognize and destroy tumor cells. Several independent approaches to the targeting of T cells against cancer have been explored, including the use of bispecific antibodies (anti-T cell/anti-tumor cell) to redirect T cells, vaccines to induce tumor-reactive T cells, and adoptive transfer of ex vivo activated, tumor-reactive T cells. In this review, we focus on studies in which high-affinity folate receptors (FRs) on tumor cells have served as targets for redirecting or enhancing the effectiveness of activated T cells. Bispecific antibody conjugates of folate and antibodies to the T cell receptor (TCR) complex can generate tumor-reactive T cell responses. The development of folate/antibody conjugates specific for the T cell co-stimulatory molecule CD28 could yield activated T cells that recognize endogenous peptide-major histocompatibility complex (MHC) antigens on tumor cells. Finally, we discuss a less investigated area in which high-affinity FRs on macrophages, or other antigen presenting cells (APCs), may provide opportunities in the design of tumor-antigen-specific vaccines.

Original languageEnglish (US)
Pages (from-to)1219-1231
Number of pages13
JournalAdvanced Drug Delivery Reviews
Volume56
Issue number8
DOIs
StatePublished - Apr 29 2004

Fingerprint

Folic Acid
T-Lymphocytes
Neoplasms
Bispecific Antibodies
Vaccines
Histocompatibility Antigens
Adoptive Transfer
Antibodies
Neoplasm Antigens
Antigen-Presenting Cells
T-Cell Antigen Receptor
Major Histocompatibility Complex
Macrophages
Peptides

Keywords

  • Antigen presenting cells
  • Folate/antibody conjugates
  • Immunotherapy
  • Macrophages
  • T cell responses

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Folate-mediated targeting of T cells to tumors. / Roy, Edward J; Gawlick, Ute; Orr, Brent A.; Kranz, David M.

In: Advanced Drug Delivery Reviews, Vol. 56, No. 8, 29.04.2004, p. 1219-1231.

Research output: Contribution to journalArticle

Roy, Edward J ; Gawlick, Ute ; Orr, Brent A. ; Kranz, David M. / Folate-mediated targeting of T cells to tumors. In: Advanced Drug Delivery Reviews. 2004 ; Vol. 56, No. 8. pp. 1219-1231.
@article{28ffec6062ad47c388219a6b20717b33,
title = "Folate-mediated targeting of T cells to tumors",
abstract = "Recently various strategies have been developed to exploit in a clinical setting the well established finding that T cells can specifically recognize and destroy tumor cells. Several independent approaches to the targeting of T cells against cancer have been explored, including the use of bispecific antibodies (anti-T cell/anti-tumor cell) to redirect T cells, vaccines to induce tumor-reactive T cells, and adoptive transfer of ex vivo activated, tumor-reactive T cells. In this review, we focus on studies in which high-affinity folate receptors (FRs) on tumor cells have served as targets for redirecting or enhancing the effectiveness of activated T cells. Bispecific antibody conjugates of folate and antibodies to the T cell receptor (TCR) complex can generate tumor-reactive T cell responses. The development of folate/antibody conjugates specific for the T cell co-stimulatory molecule CD28 could yield activated T cells that recognize endogenous peptide-major histocompatibility complex (MHC) antigens on tumor cells. Finally, we discuss a less investigated area in which high-affinity FRs on macrophages, or other antigen presenting cells (APCs), may provide opportunities in the design of tumor-antigen-specific vaccines.",
keywords = "Antigen presenting cells, Folate/antibody conjugates, Immunotherapy, Macrophages, T cell responses",
author = "Roy, {Edward J} and Ute Gawlick and Orr, {Brent A.} and Kranz, {David M}",
year = "2004",
month = "4",
day = "29",
doi = "10.1016/j.addr.2004.01.006",
language = "English (US)",
volume = "56",
pages = "1219--1231",
journal = "Advanced Drug Delivery Reviews",
issn = "0169-409X",
publisher = "Elsevier",
number = "8",

}

TY - JOUR

T1 - Folate-mediated targeting of T cells to tumors

AU - Roy, Edward J

AU - Gawlick, Ute

AU - Orr, Brent A.

AU - Kranz, David M

PY - 2004/4/29

Y1 - 2004/4/29

N2 - Recently various strategies have been developed to exploit in a clinical setting the well established finding that T cells can specifically recognize and destroy tumor cells. Several independent approaches to the targeting of T cells against cancer have been explored, including the use of bispecific antibodies (anti-T cell/anti-tumor cell) to redirect T cells, vaccines to induce tumor-reactive T cells, and adoptive transfer of ex vivo activated, tumor-reactive T cells. In this review, we focus on studies in which high-affinity folate receptors (FRs) on tumor cells have served as targets for redirecting or enhancing the effectiveness of activated T cells. Bispecific antibody conjugates of folate and antibodies to the T cell receptor (TCR) complex can generate tumor-reactive T cell responses. The development of folate/antibody conjugates specific for the T cell co-stimulatory molecule CD28 could yield activated T cells that recognize endogenous peptide-major histocompatibility complex (MHC) antigens on tumor cells. Finally, we discuss a less investigated area in which high-affinity FRs on macrophages, or other antigen presenting cells (APCs), may provide opportunities in the design of tumor-antigen-specific vaccines.

AB - Recently various strategies have been developed to exploit in a clinical setting the well established finding that T cells can specifically recognize and destroy tumor cells. Several independent approaches to the targeting of T cells against cancer have been explored, including the use of bispecific antibodies (anti-T cell/anti-tumor cell) to redirect T cells, vaccines to induce tumor-reactive T cells, and adoptive transfer of ex vivo activated, tumor-reactive T cells. In this review, we focus on studies in which high-affinity folate receptors (FRs) on tumor cells have served as targets for redirecting or enhancing the effectiveness of activated T cells. Bispecific antibody conjugates of folate and antibodies to the T cell receptor (TCR) complex can generate tumor-reactive T cell responses. The development of folate/antibody conjugates specific for the T cell co-stimulatory molecule CD28 could yield activated T cells that recognize endogenous peptide-major histocompatibility complex (MHC) antigens on tumor cells. Finally, we discuss a less investigated area in which high-affinity FRs on macrophages, or other antigen presenting cells (APCs), may provide opportunities in the design of tumor-antigen-specific vaccines.

KW - Antigen presenting cells

KW - Folate/antibody conjugates

KW - Immunotherapy

KW - Macrophages

KW - T cell responses

UR - http://www.scopus.com/inward/record.url?scp=1942439007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1942439007&partnerID=8YFLogxK

U2 - 10.1016/j.addr.2004.01.006

DO - 10.1016/j.addr.2004.01.006

M3 - Article

C2 - 15094217

AN - SCOPUS:1942439007

VL - 56

SP - 1219

EP - 1231

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

SN - 0169-409X

IS - 8

ER -